Imran Nizamuddin

Congratulations to one our outstanding @WashUHemOncFell Emily Podany @podanymd on the publication of her article "Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer" in @JAMANetworkOpen @WashUOncology jamanetwork.com/journals/jaman…

Grateful to my mentors @nehamehtashahmd and Nancy Bartlett as well as ASH @ASH_hematology for giving me the opportunity to present our work! #ASH2024

AQUILA trial for high risk smoldering myeloma published in @NEJM today. @thanosdimop Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR This story below may help those interested in a clinical trialist career. 1/

@JOEBENNETTMD @dgermain21 @NehaMehtaShahMD @SitemanCenter @WashUOncology @WashUHemOncFell Thanks, Joe! Sad we didn't get a chance to meet up this weekend!

@dgermain21 @INizMD @NehaMehtaShahMD @SitemanCenter @WashUOncology @WashUHemOncFell Congrats Imran! @INizMD #ASHKudos

Woot woot! @INizMD @NehaMehtaShahMD presenting their IIS examining acalabrutinib + durvalumab in relapsed CNS lymphoma. @SitemanCenter @WashUOncology @WashUHemOncFell

Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL sooner?! Now published in @TheLancetHaem thelancet.com/journals/lanha… (almost all patients CAR T naive) #ASH24 #lymsm

ENRICH: ibrutinib+R vs BR or RCHOP IR better PFS than RCHOP but *not* better than BR Reasonable to consider BTKi first line in patient who prefers to avoid benda but I suspect unlikely to be cost effective given continuous therapy #ASH24 #lymsm

Two big lymphoma late breaking abstracts @ASH_hematology #ASH2024 Tafa-R-Len beats R-Len in rel/ref FL ash.confex.com/ash/2024/webpr… AutoSCT not beneficial in 1L MCL if in CR/uMRD (most patients with modern induction) ash.confex.com/ash/2024/webpr…

Huge SCNSL cohort @JuanAlderuccio @CwynKate #ASH24: - 1173 pts, 45% de novo - mPFS 11 mo, mOS 21 mo (better if de novo: 13 & 47 mo) - de novo: 28% relapse post ASCT - R/R: 1-yr relapse 21% post ASCT, 56% post CAR Better OS w/ ASCT consolidation in de novo & relapsed dx. #lymsm

Nivo+AVD led to longer progression-free survival than standard BV+AVD in adolescents & adults with stage III or IV advanced-stage classic Hodgkin lymphoma & had a better side-effect profile. Results of @SWOG @COGorg S1826 in @NEJM. @DrJFriedberg @theNCI nejm.org/doi/10.1056/NE…

My favorite trial as a fellow: the MRD2STOP discontinuation trial by @bdermanmd is now published! Short thread of findings, including patient-reported outcomes (many thanks to the research team for the opportunity to integrate & analyze these PROs). #mmsm nature.com/articles/s4140…

👏👏 Kudos to Dr Mitchell Smith and @SitemanCenter Dr Brad Kahl on this large prospective, @eaonc randomized study in #MantleCellLymphoma. An important contribution to the field!

Check out our latest paper in @JCO_ASCO on surrogacy of endpoints in 1L #CLL trials! Led by @Sim_Florian, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… very important analysis!!! #lymsm

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Had the opportunity to attempt to “demystify” the fellowship application process with @docbraunstein and @chadinabhan on the Healthcare Unfiltered podcast. A great listen for those applying/planning to apply fellowship! podcasts.apple.com/us/podcast/hea…

Vorasidenib now @FDAOncology approved based off Ph3 #INDIGO for residual/recurrent Gr 2 Astrocytoma/Oligodendroglioma w/ IDH1/2 mutation! -mPFS, 27.7mos vs. 11.1mos (HR: 0.39) - Time to next intervention was significantly improved - Gr ≥ 3 AEs 22.8% #OncTwitter #NeuroOnc

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! @TheLancet @wwierda @MDAndersonNews @DrHKantarjian Chronic lymphocytic leukaemia - The Lancet thelancet.com/journals/lance…

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial - Suo - 2024 - Hematological Oncology - Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10… #leusm #AML

The most dangerous grift in ophthalmology right now is “glasses are harmful.” People that claim diet, exercise, and a 10 part instructional webinar can help you live spectacle free! No. Stop it. It’s not a big deal for most adults. They will lose some money before realizing that no amount of exercise and bull testicle consumption will fix their presbyopia. But those same adults have kids. If young kids don’t get the glasses they need, their brains won’t develop normal vision. I’m talking permanent vision loss. I have seen it happen. It’s awful and entirely preventable.

WHY I (ALMOST) NEVER BOLUS 5-FLUOROURACIL I've been pondering this thread for a while but it's become more urgent in light of another looming chemo shortage <deep sigh>, this time with an imminent dearth of THE foundational drug of GI oncology: 5-fluorouracil, or 5-FU